Vaidyanathan G, Zalutsky M R
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
Nucl Med Biol. 1995 Jan;22(1):61-4. doi: 10.1016/0969-8051(94)00078-x.
No-carrier-added [123I]MIBG was prepared from 3-(trimethylsilyl)benzylguanidine in 80-90% yield. Binding of this tracer to SK-N-SH human neuroblastoma cells maintained a constant level of > 50% over 2-3 log activity range. In comparison, the binding of [123I]MIBG prepared by isotopic exchange steadily decreased with dose. Biodistribution studies in normal mice demonstrated maximal concentrations in heart and adrenals for both preparations. In heart, significant 1.5-3.0 times higher levels (P < 0.05) were seen for the no-carrier-added preparation. Radiation dosimetry calculations suggest that the no-carrier-added preparation would increase the dose received by several tissues, most notably the heart where a 91% increase in dose is predicted.
无载体添加的[123I]间碘苄胍由3-(三甲基甲硅烷基)苄基胍制备,产率为80 - 90%。该示踪剂与SK-N-SH人神经母细胞瘤细胞的结合在2 - 3个对数活性范围内保持>50%的恒定水平。相比之下,通过同位素交换制备的[123I]间碘苄胍的结合随剂量稳步下降。正常小鼠的生物分布研究表明,两种制剂在心脏和肾上腺中的浓度最高。在心脏中,无载体添加制剂的水平显著高出1.5 - 3.0倍(P < 0.05)。辐射剂量学计算表明,无载体添加制剂会增加多个组织接受的剂量,最显著的是心脏,预计剂量会增加91%。